As of 2025-10-13, the Relative Valuation of Apellis Pharmaceuticals Inc (APLS) is (24.12) USD. This relative valuation is based on P/E multiples. With the latest stock price at 25.12 USD, the upside of Apellis Pharmaceuticals Inc based on Relative Valuation is -196.0%.
The range of the Relative Valuation is (19.37) - (27.90) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 10.7x - 15.4x | 13.4x |
| Forward P/E multiples | 7.9x - 16.9x | 13.3x |
| Fair Price | (19.37) - (27.90) | (24.12) |
| Upside | -177.1% - -211.1% | -196.0% |
| Date | P/E |
| 2025-10-10 | -13.90 |
| 2025-10-09 | -14.24 |
| 2025-10-08 | -13.79 |
| 2025-10-07 | -13.95 |
| 2025-10-06 | -13.48 |
| 2025-10-03 | -13.17 |
| 2025-10-02 | -12.79 |
| 2025-10-01 | -12.79 |
| 2025-09-30 | -12.53 |
| 2025-09-29 | -12.54 |
| 2025-09-26 | -12.38 |
| 2025-09-25 | -12.30 |
| 2025-09-24 | -12.60 |
| 2025-09-23 | -12.84 |
| 2025-09-22 | -13.00 |
| 2025-09-19 | -12.74 |
| 2025-09-18 | -12.94 |
| 2025-09-17 | -12.80 |
| 2025-09-16 | -13.18 |
| 2025-09-15 | -13.50 |
| 2025-09-12 | -13.75 |
| 2025-09-11 | -14.06 |
| 2025-09-10 | -14.41 |
| 2025-09-09 | -14.86 |
| 2025-09-08 | -14.89 |
| 2025-09-05 | -15.57 |
| 2025-09-04 | -15.86 |
| 2025-09-03 | -15.39 |
| 2025-09-02 | -15.59 |
| 2025-08-29 | -15.26 |
| 2025-08-28 | -15.53 |
| 2025-08-27 | -15.62 |
| 2025-08-26 | -15.46 |
| 2025-08-25 | -15.23 |
| 2025-08-22 | -15.48 |
| 2025-08-21 | -15.29 |
| 2025-08-20 | -14.71 |
| 2025-08-19 | -14.77 |
| 2025-08-18 | -15.14 |
| 2025-08-15 | -15.36 |
| 2025-08-14 | -15.29 |
| 2025-08-13 | -14.71 |
| 2025-08-12 | -13.23 |
| 2025-08-11 | -13.20 |
| 2025-08-08 | -13.49 |
| 2025-08-07 | -13.47 |
| 2025-08-06 | -13.13 |
| 2025-08-05 | -13.39 |
| 2025-08-04 | -13.43 |
| 2025-08-01 | -12.70 |